Maine Cancer Genomics Initiative (MCGI) Forum

Building Bridges through Genomic Medicine

February 10 – 11, 2017
Samoset Resort, Rockport, Maine

PRESENTED BY
THE JACKSON LABORATORY
AND THE HAROLD ALFOND FOUNDATION™

Building Bridges Through Genomic Medicine

Maine Cancer Genomics Initiative (MCGI) Forum

February 10 – 11, 2017 Samoset Resort, Rockport, Maine

Table of Contents

Presented by The Jackson Laboratory and The Harold Alfond Foundation™

The Jackson Laboratory

Leading the search for tomorrow's cures

www.jax.org

600 Main Street, Bar Harbor, ME 04609 | 207.288.6000

The Maine Cancer Genomics Initiative

The Maine Cancer Genomics Initiative (MCGI), enabled through generous financial support from the Harold Alfond Foundation™, leverages the strengths of key medical and bioscience research institutions in Maine to create an alliance focused on precision cancer diagnostics and treatment.

Approximately 9,000 new cancer cases occur each year in Maine. Oncologists and other healthcare providers often struggle with identifying optimal therapies for many of these patients using conventional diagnostic methods and clinical guidelines. However, the combination of genetic mutations in a tumor — its molecular signature — may be much more indicative of the appropriate treatment. In addition, a rapidly increasing body of knowledge about genomics in cancer demonstrates significant promise for treatment of cancer of all types.

The mission of the MCGI is to enable widespread access to clinical cancer genomic tests to the Maine oncology community and to increase the understanding of cancer genomics by Maine oncology clinicians. Specifically, the MCGI has four major goals. They are:

- To provide up to 1800 patients and their respective oncology clinicians in Maine with access to somatic cancer genomic tests and clinical reports from the CLIA-certified/CAP-accredited Clinical Genomics Laboratory at JAX-GM.
- To advance the field of clinical genomics by increasing knowledge about the adoption and use of these tests in the Maine community oncology setting.
- To deliver educational programs in cancer genomics and precision medicine consisting of online educational modules and MCGI-organized and supported genomic tumor boards to Maine oncology clinicians.
- To build a research network for "Community Genomic Medicine" by establishing a collaborative Maine-wide research network of cancer providers and institutions and a mechanism to enable participation of rural practices in Maine in this network.

With The Jackson Laboratory's expertise in genomic sequencing, bioinformatics, cancer analytics and drug curation, the participation healthcare professionals from Maine oncology and pathology practices and financial support from the Harold Alfond Foundation™, MCGI continues the effort to bring world-class cancer care to Maine patients.

THE HAROLD ALFOND FOUNDATION™

Founded in 1950, the Harold Alfond Foundation™ furthers the philanthropic legacy of Harold Alfond, the founder of Dexter Shoe Company and a longtime supporter of Maine communities in which he and his family worked and resided. Harold Alfond awarded matching challenge grants to organizations to build community partnerships and to inspire and leverage additional giving by others. He ensured that his philanthropy would live on by committing nearly all of his wealth to the Foundation, which continues to support charitable causes in the State of Maine.

Consistent with Harold Alfond's own giving pattern and philanthropic principles, the Foundation favors education, healthcare, youth development, and other selected charitable causes. The Foundation applies Harold Alfond's business approach to funding decisions, his belief in teamwork, and his love of competition by continuing to award matching challenge grants to projects that meet a demonstrable need, are entrepreneurial, promote teamwork, have measurable performance outcomes, are financially viable, and have quality management and board leadership.

Over the course of his life, Alfond contributed millions of dollars to charitable causes. Alfond was an accomplished athlete, a sports fan, and someone who believed strongly that athletics offer young people valuable opportunities for personal growth. Accordingly, many of Mr. Alfond's gifts were made to public and private colleges and universities and private secondary schools to construct athletic facilities and playing fields. Today, over thirty academic, athletic, healthcare, and community buildings, including Maine General's Center for Cancer Care, and facilities bear the Alfond name. The Foundation's grants for capital projects to educational institutions have often included a requirement for scholarships, including programs at the University of Maine, Colby College, St. Joseph's College, Husson College, and others. Over 600 students have received Alfond scholarships since 1950.

THE JACKSON LABORATORY

At The Jackson Laboratory (JAX), we apply passion, innovation and ever-increasing precision to make this vision a reality. We are accelerating disruptive scientific breakthroughs tailored to the needs of individual patients and closing in on the genetic and molecular courses of disease. We also educate current and future scientists and empower the global biomedical community by providing critical resources, data, tools and services.

Founded in 1929, The Jackson Laboratory (JAX) is an independent, nonprofit biomedical research institution with more than 1,800 employees who are passionate about our mission: to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.

JAX has a mammalian genetics headquarters in Bar Harbor, Maine; a facility in Sacramento, Calif.; and a new genomic medicine facility in Farmington, Conn. that is enabling the Laboratory to translate its fundamental science into the clinic. In addition to its National Cancer Institute-designated Cancer Center, the Laboratory also has initiated a cancer research laboratory in Seoul, Korea.

The Jackson Laboratory has more than 60 principal investigators who come together from diverse backgrounds and areas of expertise to advance mammalian genetics and human genomics research in aging, behavioral disorders, bioinformatics, cancer, complex traits, developmental disorders, diabetes and obesity, eye research, genetics and genomics, immune disorders, infectious diseases, neurodegenerative and neuromuscular diseases, reproductive disorders, resource development, and skin disease.

From high school summer programs to graduate and postdoctoral training to conferences that further the education of practicing scientists and professionals, The Jackson Laboratory advances science and improves health through our commitment to education.

Jax® Mice, Clinical & Research Services at The Jackson Laboratory is a global resource for developing, distributing and analyzing innovative models of human disease. It offers an array of model creation, husbandry and diagnostic and analytic services, ranging from custom breeding and strain preservation to drug efficacy studies and genome sequencing, all focused on empowering basic scientific research and drug discovery.

Agenda

As a leader in cancer research in Maine, The Jackson Laboratory (JAX) has partnered with clinical institutions and oncology practices in Maine to help cancer patients across the state. Maine oncology providers face the challenges of having one of the highest cancer incidences in the country, along with a rapid evolution in the care and treatment options for cancer patients in their practices. As a member of the Maine community, The Jackson Laboratory believes that by collaborating with experts in Maine there is an opportunity to do more for Maine cancer patients.

The February 2017 forum will focus on:

- An introduction to the Maine Cancer Genomics Initiative (MCGI).
- Identifying physician educational program needs focused on genomic cancer education, including genomic testing and genomic tumor boards.
- Building a collaborative network of oncology healthcare providers that will facilitate the further growth of genomic medicine research initiatives

Friday, February 10, 2017

4:00 p.m. *Arrival and Check in begins*

5:30 p.m. Steering Committee Meeting — members only

7:00 p.m. **DINNER AND WELCOME**

Introductions and Acknowledgements
Jens Rueter, M.D. | The Jackson Laboratory

Opening Address
Edison T Liu, M.D. | The Jackson Laboratory

Informal Q&A in the pub with
Edison T Liu, M.D., Chuck Hewett, Ph.D., Jens Rueter, M.D., and Andrey Antov, Ph.D. | The Jackson Laboratory

Saturday, February 110, 2017

8:00 a.m. *Breakfast*

8:20 a.m. **OPENING REMARKS**
Jens Rueter, M.D. | The Jackson Laboratory

8:30 a.m. **SESSION 1**
Real World Applications: Using Precision Medicine Tools

8:30 a.m. Genomic Sequencing Technology: Finding what's wrong
Honey Reddi, Ph.D., FACMG | The Jackson Laboratory

8:50 a.m. Genomic Sequencing Technology:
Curation — putting what's wrong into perspective
Susan Mockus, Ph.D. | The Jackson Laboratory

9:10 a.m. Questions and Panel discussion
Honey Reddi, Ph.D. and Susan Mockus, Ph.D.
Moderator: Andrey Antov, Ph.D.

9:30 a.m. Video: Exploring Somatic Cancer Panel Testing

9:40 a.m. *Break*
Refreshments and Networking, hotel check out

10:00 a.m. **SESSION 2**
Real World Applications: The Clinical Impact of Precision Medicine

10:00 a.m. "Mock" Genomic Tumor Board: Case presentations
Antoine Harb, M.D. | Eastern Maine Medical Center
Marek Skacel, M.D. | Dahl Chase
Christian Thomas, M.D. | New England Cancer Specialists
Robert Christman, M.D. | Spectrum Medical Group

Genomic Tumor Board: Case Discussion
Susan Mockus, Ph.D. and Honey Reddi, Ph.D. | The Jackson Laboratory
Michael Hall, M.D. | Fox Chase Cancer Center
Christopher Gocke, M.D. | Johns Hopkins

Genomic Tumor Board: Audience Questions and Discussion
Moderator: Jens Rueter, M.D.

11:00 a.m. *Break*

11:20 a.m. MCGI — A Maine Oncology Network empowering Precision Medicine.
Overview of protocol and discussion
Jens Rueter, MD, Andrey Antov, Ph.D. | The Jackson Laboratory

12:30 p.m. *Lunch*

1:30 p.m. **FORUM ADJOURNED**
Drs. Rueter, Antov, and select presenters available for informal Q&A

Forum Presenters

MAINE CANCER GENOMICS INITIATIVE (MCGI)

Robert Christman, M.D.

Dr Christman is the Maine Medical Center Pathology Department Chief and Spectrum Pathologist with Spectrum Medical Group. He holds board certification from the American Board of Pathology and specializes in Pathology & Laboratory Medicine. Dr Christman received his MD from Temple University School of Medicine, where he also served his residency and held a fellowship position.

Christopher Gocke, M.D.

Dr. Christopher Gocke is an Associate Professor of Pathology and Oncology at the Johns Hopkins University School of Medicine. He is Director of the Division of Molecular Pathology, Deputy Director (Vice Chairman) of Personalized Medicine for the Department of Pathology, and co-director of Johns Hopkins Genomics. He received his B.A. in Chemistry from Princeton University and his M.D. in 1985 from Rutgers Medical School. His residency training in pathology was at the University of Rochester and Stanford University, where he was Chief Resident. He completed a fellowship in pathology at Stanford. Dr. Gocke has co-authored over 125 peer-reviewed publications in the area of cancer diagnostics. He is a past Councilor on the Program Directors' Council of the Association of Molecular Pathology and a member of the NCI's Investigational Drug Steering Committee. He is co-principle investigator on two NIH research project cooperative agreements. He is board certified in Molecular Genetic Pathology and Anatomic Pathology.

Michael Hall, M.D., M.S.

Dr Hall practices oncology at Fox Chase Cancer Center. He is the director of the Gastrointestinal Risk Assessment Program. His professional interests include treatment of GI cancers and risk assessment/cancer risk mitigation in patients and family members through hereditary genetic testing and cancer prevention counseling. His research interests include health services research related to GI oncology and hereditary cancer risk, gene discovery in high risk families with GI and rare cancers, and development of EHR-based tools/applications to deliver genetic risk information to patients. Dr Hall is board certified in Hematology and Medical Oncology. He received his MD from Columbia College of Physicians & Surgeons followed by an internship and residency in Internal Medicine at Brigham and Women's Hospital. Dr Hall also completed a fellowship in Hematology/Oncology at University of Chicago and at Columbia University/Mailman School of Public Health, as well as a Masters in Health Services Research.

Antoine Harb, M.D.

Dr Harb practices oncology at Eastern Maine Medical Center. He is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr Harb is affiliated as well with Blue Hill Memorial Hospital. He takes a special interest in thoracic, head and Neck and Neuro-oncology. Dr Harb received his MD from Saint Joseph University, where he also served his residency in Internal Medicine. Later Dr Harb did an additional residency at University at Buffalo followed by a fellowship in Hematology/Oncology at UMDNJ (University of Medicine and Dentistry of New Jersey)-Cooper Medical Center.

Edison Liu, M.D.

Dr. Liu is the president and CEO of The Jackson Laboratory. Previously, he was the founding executive director of the Genome Institute of Singapore (2001-2011), and was the president of the Human Genome Organization (HUGO) from 2007-2013. Between 1997 and 2001, he was the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md., where he was in charge of the intramural clinical translational science programs. From 1987 to 1996, Dr. Liu was a faculty member at the University of North Carolina at Chapel Hill, where he was the director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence in Breast Cancer; the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health; chief of Medical Genetics; and the chair of the Correlative Science Committee of the national cooperative clinical trials group, CALGB. Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology and translational medicine. Dr. Liu's own scientific research has focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering on a genomic scale the dynamics of gene regulation that modulate cancer biology. He has authored over 300 scientific papers and reviews, and co-authored two books. He obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford. From 1982 to 1987 he was at the University of California, San Francisco, at the G.W. Hooper Foundation.

Sue Mockus, Ph.D.

Dr. Mockus is the Manager of Clinical Analytics and Curation at The Jackson Laboratory for Genomic Medicine, where she pioneered the development of a clinical knowledgebase (ckb.jax.org) to support

interpretation of next-generation sequencing data. Dr. Mockus continues to oversee the JAX clinical interpretation group while developing internal and external partnerships to foster advancements in the capture, analysis, and utilization of big-data. Her focus is on the development of efficient workflow processes and tools for interpretation of NGS assays through close collaboration with software engineers and IT personnel. At the Jackson Laboratory, she applies over ten years of experience in biocuration to enable clinical reporting of genomic sequencing data and has numerous abstracts and publications on the topic. She received her Ph.D. from Wake Forest University in neuroscience with a minor in pharmacology. After completing postdoctoral training in the department of pharmacology at the University of Washington in Seattle, WA, she began her industry career with Biobase, where she was the Product Manager of the Human Disease knowledgebase (HGMD). Her role on the MCGI task force is to assess data management solutions by defining core functionalities, identifying multiple system touch points, and establishing requirements for integration of clinical and genomic data.

Honey Reddi, Ph.D., F.A.C.M.G.

Dr. Reddi is the Clinical Lab Director of the CLIA/CAP accredited Clinical Genomic Services laboratory at JAX Genomic Medicine. She comes to JAX from Transgenomic Inc., where she held the role of Vice President for Clinical Operations and Clinical Lab Director. She earned her Ph.D. in Biotechnology from the International Center for Genetic Engineering & Biotechnology (ICGEB) and Hamdard University (New Delhi, India), and completed a fellowship with the Mayo Clinic (Rochester, MN) in Clinical Molecular Genetics. Dr. Reddi is an ABMGG-certified Molecular Geneticist with research interests in cancer, viro-therapeutics and the genetics of inherited disorders. The clinical lab offers a variety of diagnostic tests for somatic variant detection in Oncology as well as helps facilitate the translation of assays from research to the clinic for Principal investigators at JAX. In her role as the laboratory director, Dr. Reddi also actively interacts with the oncologists/ordering physician to ensure that appropriate test utilization and provide post-test follow-up.

Jens Rueter, M.D.

Dr. Rueter is the Medical Director for the MCGI. He joined JAX for this position in August 2016. Dr. Rueter came to JAX from Eastern Maine Medical Center Cancer Care in Brewer, Maine, where he was the medical director for EMMC'S Translational Oncology Program and the Oncology Biobank. He has been a hematologist/oncologist at EMMC Cancer Care since 2010, and a member of the JAX adjunct faculty since 2012. Dr. Rueter has collaborated with several JAX investigators and technicians on developing new approaches to treating cancers while advancing translational research at EMMC. After graduating from medical school in Berlin, Germany, Rueter completed his residency in internal medicine at Tulane University and fellowship training in hematology/oncology at the University of Pennsylvania.

Marek Skacel, M.D.

Dr Skacel is a Pathologist at Dahl-Chase Pathology Associates in Bangor, ME. He is holds board certifications from the American Board of Pathology in Anatomic and Clinical Pathology and Hematopathology. He takes a special interest in the areas of Gastrointestinal Pathology, Genitourinary Pathology, Soft Tissue Pathology, Hematopathology, and Molecular Pathology. Dr Skacel received his MD followed by an internship at Palacky University in Olomouc, Czech Republic. Subsequently he completed residency in Anatomic and Clinical Pathology at The Cleveland Clinic Foundation followed by fellowships in Gastrointestinal, Genitourinary & Soft Tissue Pathology, Molecular Pathology Research, Hematopathology, and Surgical Pathology.

Christian Thomas, M.D.

Dr. Thomas was born and raised near Frankfurt, Germany. In 1990 after graduating from Goethe University Medical School in Germany, he came to Columbia University in New York City to work on a research project and then stayed to complete his residency in Internal Medicine and a Fellowship in Hematology and Oncology. Dr. Thomas met his wife, Elizabeth, in New York and after completing his fellowship they decided they were ready to leave the city for the fresh air and mountains of Vermont. They moved in 1999. He became a partner in a hematology/oncology practice in Colchester, and he and his family stayed to enjoy the beauty of the Green Mountain State for 13 years. In 2012, he was delighted to have the opportunity to come to Maine to work at New England Cancer Specialists as a physician and the Director of Clinical Research. His clinical focus is on thoracic cancers (lung cancer, esophageal cancer) as well as GU cancers (prostate, testicular, bladder and kidney cancers). He also serves as an advisor to the American Society of Clinical Oncology, the Northern New England Clinical Oncology Society and CMS/Medicare. He lives in Portland with his wife, a photographer, his three daughters and two dogs. In his free time he enjoys rowing, cooking, playing squash and getting to know the great state of Maine.

Steering Committee

MAINE CANCER GENOMICS INITIATIVE (MCGI)

Philip L. Brooks, M.D.

Dr Brooks practices at Eastern Maine Medical Center and oversees their clinics at the Mt. Desert Island Hospital, the Maine Coast Memorial Hospital, and the Blue Hill Memorial Hospital. He is board certified in Internal Medicine, Hematology, and Medical Oncology caring for patients in all areas of medical oncology, hematologic oncology, and benign hematology. He received his MD from the University of Pennsylvania School of Medicine then completed his Medical Residency at the University of Pennsylvania- Presbyterian Medical Center. Following that he completed a 3 year fellowship in Hematology/Oncology at Dartmouth-Hitchcock Medical Center. Dr. Brooks arrived at Eastern Maine Medical Center's Oncology program in 1980 and has held many leadership positions over those years. He spent 2 ½ years in China as Sr. Vice-President of Medical Affairs and Chief of Oncology Development for United Family Healthcare and returned to Eastern Maine Medical Center in 2011. He now lives with his wife, Astri, in Bar Harbor, Maine.

Robert Christman, M.D.

Dr Christman is the Maine Medical Center Pathology Department Chief and Spectrum Pathologist with Spectrum Medical Group. He holds board certification from the American Board of Pathology and specializes in Pathology & Laboratory Medicine. Dr Christman received his MD from Temple University School of Medicine, where he also served his residency and held a fellowship position.

Elizabeth (Betsy) Connelly, D.O.

Dr Connelly practices medical oncology and hematology at Waldo County General Hospital. She is board certified in Medical Oncology, Hematology, and Internal Medicine. Dr Connelly is a member in the American Society of Clinical Oncology and is on active staff at Waldo County and Pen Bay Medical Center. She received her DO from Texas College of Osteopathic Medicine followed by a residency at Akron General Medical Center in Internal Medicine and a Fellowship with the Cleveland Clinic Foundation in Medical Oncology/ Hematology.

Topher Darus, M.D.

Dr Darus practices Gynecologic Oncology at Maine Medical Partners. He holds board certification from the American Board of Obstetrics and Gynecology and specializes in Gynecologic Oncology. Dr Darus received his MD from Wright State University School of Medicine, followed by a residency at University of Colorado Health Sciences Center and a Fellowship at University of Virginia Medical Center.

Nicholette L. Erickson, M.D.

Dr Erickson practices at Hematology-Oncology Associates in Lewiston, ME. She is board certified in Hematology and Medical Oncology. She received her MD from Medical College of Virginia followed by a residency in Internal Medicine and a Fellowship with the University of Virginia Health Sciences Center in Hematology-Oncology.

Allan V. Espinosa, M.D.

Dr Espinosa is hematologist/oncologist working in Northern Maine (Cary Medical Center, Northern Maine Medical Center and Millinocket Regional Hospital). He has been in the community for 3 years. His professional interests include thyroid cancer, melanoma, lung cancer and neuroendocrine tumors. Dr Espinosa serves as Associate faculty at Tufts University Medical School through Cary Medical Center. He received his MD from Medical School at Universidad Americana in Managua, Nicaragua followed by a Postdoctoral fellowship in thyroid cancer basic science research at The Ohio State University, a residency in Internal Medicine at The Ohio State University and a Fellowship in Hematology-Oncology at Vanderbilt University. In his leisure time Dr Espinosa can be found biking, cycling, snowmobiling.

Peter Georges, M.D.

Dr Georges practices Oncology at York Hospital in Southern Maine. He holds board certification in internal medicine, Hematology and medical oncology. His interests include traveling and scuba diving. Dr Georges received his MD from Georges University School of Medicine in Grenada; West Indies followed by an internship and residency at University of Massachusetts. He completed his fellowship in Hematology-Oncology at Anderson Cooper Cancer Center, Cooper Medical School of Rowan University.

Antoine Harb, M.D.

Dr Harb practices oncology at Eastern Maine Medical Center. He is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr Harb is affiliated as well with Blue Hill Memorial Hospital. He takes a special interest in thoracic, head and Neck and Neuro-oncology. Dr Harb received his MD from Saint Joseph University, where he also served his residency in Internal Medicine. Later Dr Harb did an additional residency at University at Buffalo followed by a fellowship in Hematology/ Oncology at UMDNJ (University of Medicine and Dentistry of New Jersey)-Cooper Medical Center.

Roger C. Inhorn, M.D., Ph.D.

Roger Inhorn is the Chief of Oncology at Mercy Hospital in Portland, Maine. A native Madisonian, he studied mathematics and molecular biology at the University of Wisconsin. He is a graduate of the MD/PhD program at Washington University Medical School. He completed his internal medicine residency at Brigham and Women's Hospital followed by a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Inhorn practiced in St. Louis for 7 years, where he was associate director of hematology/oncology at St. John's Mercy Medical Center, prior to relocating to Maine. He has a special interest in breast cancer and clinical trials. He lives with his wife and four children in Cape Elizabeth.

Edison Liu, M.D.

Dr. Liu is the president and CEO of The Jackson Laboratory. Previously, he was the founding executive director of the Genome Institute of Singapore (2001-2011), and was the president of the Human Genome Organization (HUGO) from 2007-2013. Between 1997 and 2001, he was the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md., where he was in charge of the intramural clinical translational science programs. From 1987 to 1996, Dr. Liu was a faculty member at the University of North Carolina at Chapel Hill, where he was the director of the UNC Lineberger Comprehensive

Cancer Center's Specialized Program of Research Excellence in Breast Cancer; the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health; chief of Medical Genetics; and the chair of the Correlative Science Committee of the national cooperative clinical trials group, CALGB. Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology and translational medicine. Dr. Liu's own scientific research has focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering on a genomic scale the dynamics of gene regulation that modulate cancer biology. He has authored over 300 scientific papers and reviews, and co-authored two books. He obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford. From 1982 to 1987 he was at the University of California, San Francisco, at the G.W. Hooper Foundation.

Robin Locke, M.D.

Dr. Locke is a medical oncologist/hematologist at the Harold Alfond Center for Cancer Care. Her practice includes care for patients with a range of diagnoses, with a particular clinical interest in breast cancer. Dr Locke received her MD from the Albert Einstein College of Medicine followed by a residency at the Jacobi Medical Center & Jack D. Weiler Hospital, Albert Einstein College of Medicine. She also held a fellowship in Hematology and Medical Oncology at Montefiore Medical Center.

Mayur K. Movalia, M.D.

Dr Movalia is a Pathologist with Dahl-Chase Pathology Associates in Bangor, ME. He is holds board certifications from the American Board of Pathology in Anatomic and Clinical Pathology and Hematopathology. Dr Movalia received his MD from Flinders University School of Medicine followed by an internship in Internal Medicine and pathology residency at University of Hawaii as well as a Hematopathology Fellowship at Hartford Hospital.

G. Richard Polkinghorn, M.D.

Dr Polkinghorn was a practicing oncologist at Maine Medical Center and Mid Coast Hospital for 14 years prior to coming to Maine General Medical Center. His professional interests include breast cancer and lung cancer involving novel and targeted therapies. Dr Polkinghorn received his MD from Case Western Reserve University followed by an internship and residency in Internal Medicine at UCLA Medical Center in Los Angeles, CA and a fellowship in Medical Oncology at Harbor UCLA Medical Center in Torrance, CA.

Karen Rasmussen, Ph.D., F.A.C.M.G.

Dr Rasmussen is Director of Molecular Genetics at Spectrum Medical Group. She has extensive experience in Clinical Molecular Genetics: development and interpretation of molecular genetic assays, including next-generation sequencing and gene expression profiling. Dr Rasmussen has provided cancer genetic counseling in the community oncology setting. She also has experience in tumor tissue banking for research and has worked in cancer molecular genetic research, primarily identifying mutational or gene expression profiles of tumors for prognosis or prediction of response to therapy. Dr Rasmussen received her PhD from University of New Hampshire followed by a fellowship in Clinical Molecular Genetics at the University of North Carolina School of Medicine.

Scot Remick, M.D.

Dr Remick is Physician Leader of Oncology at Maine Medical Center Cancer Institute and Maine Health, where he specializes in Internal Medicine, and Oncology. He board certified in Internal Medicine with subspecialty of oncology. Dr Remick received his MD from New York Medical College followed by a residency at Johns Hopkins Baltimore City Hospital and fellowship at University of Wisconsin Hospitals & Clinics.

Peter Rubin, M.D.

Dr Rubin practices oncology at SMHC Cancer Care Center, and is Medical Director. His professional interests include clinical and translational research. He is board certified in Hematology and Medical Oncology. Dr Rubin received his MD from University of Calgary followed by residencies at University of Calgary, University of Western Ontario, and University of Western Ontario-Schulich School of Medicine & Dentistry. He also held a fellowship at Duke University Medical Center.

Sarah Sinclair, D.O.

Dr Sinclair practices oncology at EMMC CancerCare of Maine. She is board certified in Internal Medicine, and Medical Oncology. Her interests include breast cancer, clinical research, and general oncology. Dr Sinclair received her DO from University of New England College of Osteopathic Medicine followed by a residency at University of Connecticut School of Medicine in Internal Medicine and a Fellowship with the National Cancer Institute in Hematology/Oncology.

Marek Skacel, M.D.

Dr Skacel is a Pathologist at Dahl-Chase Pathology Associates in Bangor, ME. He is holds board certifications from the American Board of Pathology in Anatomic and Clinical Pathology and Hematopathology. He takes a special interest in the areas of Gastrointestinal Pathology, Genitourinary Pathology, Soft Tissue Pathology, Hematopathology, and Molecular Pathology. Dr Skacel received his MD followed by an internship at Palacky University in Olomouc, Czech Republic. Subsequently he completed residency in Anatomic and Clinical Pathology at The Cleveland Clinic Foundation followed by fellowships in Gastrointestinal, Genitourinary & Soft Tissue Pathology, Molecular Pathology Research, Hematopathology, and Surgical Pathology.

Christian Thomas, M.D.

Dr. Thomas was born and raised near Frankfurt, Germany. In 1990 after graduating from Goethe University Medical School in Germany, he came to Columbia University in New York City to work on a research project and then stayed to complete his residency in Internal Medicine and a Fellowship in Hematology and Oncology. Dr. Thomas met his wife, Elizabeth, in New York and after completing his fellowship they decided they were ready to leave the city for the fresh air and mountains of Vermont. They moved in 1999. He became a partner in a hematology/oncology practice in Colchester, and he and his family stayed to enjoy the beauty of the Green Mountain State for 13 years. In 2012, he was delighted to have the opportunity to come to Maine to work at New England Cancer Specialists as a physician and the Director of Clinical Research. His clinical focus is on thoracic cancers (lung cancer, esophageal cancer) as well as GU cancers (prostate, testicular, bladder and kidney cancers). He also serves as an advisor to the American Society of Clinical Oncology, the Northern New England Clinical Oncology Society and CMS/Medicare. He lives in Portland with his wife, a photographer, his three daughters and two dogs. In his free time he enjoys rowing, cooking, playing squash and getting to know the great state of Maine.

Maine Cancer Genomics Initiative (MGCI)

- FREE CANCER GENOMIC TESTS
- CANCER GENETICS EDUCATION
- FOUNDATION FOR A MAINE-WIDE COLLABORATION
- GENOMIC MEDICINE STUDIES



Attendee List

MAINE CANCER GENOMICS INITIATIVE (MCGI)

Andrey Antov
The Jackson Laboratory

Fred Aronson
New England Cancer Specialists

Sigrid Berg
EMMC Cancer Care

Timothy Bilodeau
Maine Research Associates

Jennifer Bourne
The Jackson Laboratory

Philip Brooks
CancerCare of Maine
Eastern Maine Medical Center

Jessica Cary
New England Cancer Specialists

Robert Christman
Spectrum Medical Group

Elizabeth Connelly
Waldo County Health Care
Pen Bay Health Care

Stephen D'Amato
New England Cancer Specialists

Julie Davis
York Hospital

Steven Diaz
MaineGeneral Health

Nicolette Erickson
Central Maine Medical Center

Danielle Fogg
Cancer Care of Maine

Regen Gallagher
Cary Medical Center

Peter Georges
York Hospital

Michael Hall
Fox Chase Cancer Center

Paul Han
Maine Medical Center

Antoine Harb
EMMC Cancer Care

Charles Hewett
The Jackson Laboratory

Helen Hsu
EMMC Cancer Care

Roger Inhorn
Mercy Hospital Oncology Program

Thomas Keating
New England Cancer Specialists

Caroline Knight
Pen Bay Medical Center

Laurie Lewis
EMMC Cancer Care

Allen L'Italien
Eastern Maine Medical Center

Edison Liu
The Jackson Laboratory

Na Liu
St Mary's Hospital

Kathy Malatesta
Harold Alfond Center for Cancer Care

Marilyn McLaughlin
York Hospital

Susan Mockus
The Jackson Laboratory

Hussain Naseri
TAMC

Crystal Nayock
Maine Research Associates
Central Maine Medical Center

Laura Nelsen
MaineGeneral Medical Center

Sandra Neptune
Harold Alfond Center for Cancer Care

Diana Porter
Cancer Care of Maine

Nadia Rajack
Cary Medical Center

Nadia Ramdin
Harold Alfond Center for Cancer Care

Karen Rasmussen
Spectrum Pathology

Honey Reddi
The Jackson Laboratory

Scot Remick
Maine Medical Center Cancer Institute

Peter Rubin
Southern Maine Health Care

Jens Rueter
The Jackson Laboratory

Sarah Sinclair
EMMC Cancer Care

Donald St. Germain
Maine Medical Center

Christian Thomas
New England Cancer Specialists

Kathleen Vieira
Central Maine Hematology Oncology

Tracey Weisberg
New England Cancer Specialists

Colleen Yavarow
York Hospital

Eva Zaslavsky
SMHC



“Leading the Search for Tomorrow’s Cures”

— THE JACKSON LABORATORY

“Don’t Tell Me, Show Me”

— HAROLD ALFOND